FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 314:65-70 January 9, 1986 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In a double-blind evaluation of alpha 2-interferon as prophylaxis against naturally acquired respiratory infections, 120 adult members of 46 Australian families used 325 courses of intranasal spray during a six-month period, applying 5 million IU to the anterior nasal mucosa daily for seven days when respiratory symptoms developed in another member of the family. Used in this way, the alpha 2-interferon was well tolerated, and the rate of minor nasal bleeding (12 percent) did not increase with repeated courses. By comparison with the control group of 109 members of 49 families who used 319 seven-day courses of placebo spray, the users of alpha 2-interferon experienced 33 percent fewer days with nasal symptoms and 41 percent fewer episodes of "definite" respiratory illness. The users of alpha 2-interferon who were exposed to rhinovirus infections experienced 76 percent fewer days with symptoms and 86 percent fewer "definite" illnesses than their counterparts who used placebo. All of the observed clinical benefits, which suggested prevention of 6.8 "definite" respiratory illnesses per 100 courses of medication used, could be explained by a protective effect against illness associated with rhinoviruses that was not demonstrated for influenza A or B or coronavirus 229E.

This article has been cited by other articles:

• Turner, R. B., Wecker, M. T., Pohl, G., Witek, T. J., McNally, E., St. George, R., Winther, B., Hayden, F. G. (1999). Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A Randomized Clinical Trial. JAMA 281: 1797-1804 [Abstract] [Full Text]  
• McIntosh, K. (1999). Closer to a Cure for the Common Cold?. JAMA 281: 1844-1845 [Full Text]  
• Baron, S., Tyring, S. K., Fleischmann, W. R. Jr, Coppenhaver, D. H., Niesel, D. W., Klimpel, G. R., Stanton, G. J., Hughes, T. K. (1991). The Interferons: Mechanisms of Action and Clinical Applications. JAMA 266: 1375-1383 [Abstract]  
• Gorman, S. E., Plaisance, K. (1991). Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice 4: 103-116  
• FAUCI, A. S., ROSENBERG, S. A., SHERWIN, S. A., DINARELLO, C. A., LONGO, D. L., LANE, H. C. (1987). Immunomodulators in Clinical Medicine. ANN INTERN MED 106: 421-433 [Abstract]  
• FAHEY, J. L., SARNA, G., GALE, R. P., SEEGER, R. (1987). Immune Interventions in Disease. ANN INTERN MED 106: 257-274 [Abstract]